David Neal Franz, MD
- Founding Director, Tuberous Sclerosis Clinic
- Associate Director of Clinical Affairs, Division of Neurology
- Professor, UC Department of Pediatrics
- david.franz@cchmc.org
- Board Certified
About
Biography
As a brain doctor, I care for children with general neurologic conditions. I specialize in neurocutaneous disorders and neuropharmacology. I’m the founding director of the Tuberous Sclerosis Clinic at Children’s Hospital Medical Center.
I believe in providing the best care and treatment for my patients and families, whatever that may be.
At Cincinnati Children’s we try our sincere best to help patients and families living with a complex neurological and medical diagnosis. Many of these conditions do not have established or approved therapies.
My research focuses on targeted therapies for epilepsy and genetic brain disorders.
MD: Ohio State University College of Medicine, Columbus, OH, 1985.
Residency: Wright State University Affiliated Hospitals, Dayton, OH.
Fellowship: Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 1990, 2016; Neurology with special competence in child neurology, 1992.
Interests
Tuberous sclerosis (adults and children); neuropharmacology; neurocutaneous disorders; general pediatric neurology
Services and Specialties
Research Areas
Additional Languages
GermanLocations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Long-Term Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Treatment for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis. Pediatric Neurology. 2025; 168:90-95.
Treating subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: an update of the literature. Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders. 2025; 25:389-396.
Cenobamate's Efficacy for Seizure Treatment in Tuberous Sclerosis Complex. Pediatric Neurology. 2024; 161:201-207.
Mammalian Target of Rapamycin Inhibitor Levels Decrease Under Cenobamate Treatment. Pediatric Neurology. 2024; 161:73-75.
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results. 2024; 2:106-119.
Stiripentol for Drug-Resistant Epilepsy Treatment in Tuberous Sclerosis Complex. Pediatric Neurology. 2023; 139:86-92.
Prevalence of thoracoabdominal imaging findings in tuberous sclerosis complex. Orphanet Journal of Rare Diseases. 2022; 17:124.
Changing the outcome in genetic brain disorders. Developmental Medicine and Child Neurology. 2022; 64:1184-1185.
Cellular and molecular characterization of two novel asparagine synthetase gene mutations linked to asparagine synthetase deficiency. The Journal of biological chemistry. 2022; 298:102385.
Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). Journal of Neurodevelopmental Disorders. 2021; 13:60.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey